Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (QoQ) (2009 - 2026)
Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - |
| 10 | Moderna | 28.64 Bn | 23.43 Bn | -566.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.91% |
| Dec 31, 2025 | -146.24% |
| Sep 30, 2025 | 75.85% |
| Jun 30, 2025 | -768.28% |
| Mar 31, 2025 | 93.21% |
| Dec 31, 2024 | -136.18% |
| Sep 30, 2024 | 24.95% |
| Jun 30, 2024 | 78.30% |
| Mar 31, 2024 | -140.99% |
| Dec 31, 2023 | -653.19% |
| Sep 30, 2023 | 61.27% |
| Jun 30, 2023 | 83.43% |
| Mar 31, 2023 | -1,144.19% |
| Dec 31, 2022 | 145.71% |
| Sep 30, 2022 | -524.72% |
| Jun 30, 2022 | -20.59% |
| Mar 31, 2022 | 61.94% |
| Dec 31, 2021 | -153.31% |
| Sep 30, 2021 | 33.63% |
| Jun 30, 2021 | -7.27% |